<DOC>
	<DOCNO>NCT01559961</DOCNO>
	<brief_summary>The purpose study determine safety pharmacokinetics TTI-1612 woman interstitial cystitis/bladder pain syndrome .</brief_summary>
	<brief_title>Safety Study Single Intravesical Doses TTI-1612 Women With Interstitial Cystitis/Bladder Pain Syndrome</brief_title>
	<detailed_description>Single dose TTI-1612 , seven escalate dose level , administer intravesically woman IC/BPS . Drug retain bladder 30 minute . TTI-1612 pharmacokinetics study collection blood sample various time point , 5 minute 8 hour post administration dose day , 24 48 hour post dose . Serum isolate subsequent analysis determination follow parameter : maximum serum concentration ( Cmax ) , time maximum observed concentration ( Tmax ) , area curve final time concentration limit quantification ( AUC 0-t ) infinity ( AUC 0-∞ ) , elimination half-life ( t½ ) , clearance ( CL ) volume distribution ( Vz ) . TTI-1612 safety determine monitoring subject ' vital sign , ECGs , clinical laboratory evaluation , adverse event ( ) physical examination .</detailed_description>
	<mesh_term>Cystitis</mesh_term>
	<mesh_term>Cystitis , Interstitial</mesh_term>
	<criteria>Subject female , 18 65 year old , inclusive . Subject read sign ICF . Subject BMI 18 32kg/sq.m. , inclusive . Subject diagnosed IC/BPS , accord current AUA guideline IC/BPS . Subjects childbearing potential must agree : ( 1 ) doublebarrier contraception method screen baseline visit , ( 2 ) abstain sexual intercourse baseline visit study completion ( day 7 +/ 1 day ) . Subject negative serum pregnancy test screen baseline . Subject lactating . Subject document negative antibody test HIV , HbSAg HCV within 3 month prior dose test negative screening . Subject test negative bladder cancer cystoscopy within 6 month prior dose test negative urine cytology screen . Subject clinical laboratory value ( CBCs , comprehensive metabolic panel urinalysis ) fall within normal range clinically significant opinion Investigator . Subject history oncologic disease except nonmelanoma skin cancer . Subject condition , opinion Investigator , may jeopardize safety subject may impact validity study result . Subject , whatever reason , substantial change eat habit within 30 day prior dose , , opinion Investigator , may confound plan PK evaluation interpretation result study . Subject donate blood within 30 day plasma within 14 day prior dose . Subject use intravesical therapy within 3 month prior dose . Subject receive nonstable therapy IC/BPS ( stable therapy define continuous treatment least 6 month ) . Subject use investigational agent within 3 month prior dose . Subject ECG vital sign baseline , opinion Investigator Sponsor , is/are clinically significant . Subject consume alcohol , grapefruit , grapefruit juice xanthinecontaining beverage food within 48 hour prior dose . Subject take know hepatic enzymealtering drug within 30 day prior dose . Subject take known heparincontaining drug within 30 day prior dose .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>bladder</keyword>
	<keyword>cystitis</keyword>
	<keyword>frequency</keyword>
	<keyword>nocturia</keyword>
	<keyword>pain</keyword>
	<keyword>urgency</keyword>
</DOC>